Medtronic has formally wrapped up its separation from MiniMed, accepting roughly 55 million of its own shares in exchange for the last block of stock it still held in the former subsidiary. The medical device maker disclosed the final tally of its exchange offer, which expired on October 9, confirming that it no longer owns any stake in the diabetes business it once controlled.
Exchange Terms and Allocation
The offer drew demand well beyond what Medtronic was prepared to absorb. In total, the company took back 55,032,401 of its own common shares and handed over all 252,813,348 remaining MiniMed shares to participating investors. Because the book was oversubscribed, shareholders who tendered outside of eligible small holdings received just 18.289133 percent of what they put forward, with the balance returned to them.
The final exchange ratio came in at 4.5939 MiniMed shares for every accepted Medtronic share. Cancelling the tendered stock trims the company’s outstanding share count, concentrating future earnings across a smaller base — a mechanical effect that stands to support earnings per share down the road. It also marks the end of a strategic retreat from the U.S. insulin pump market, where revenue had been under pressure.
Market Response and Analyst Adjustments
Investors took the completion in stride. The stock finished Wednesday’s European session at EUR 84.46, up 1.7 percent, and now trades 6.9 percent above its 50-day moving average. By the following session it had settled at EUR 84.34, a dip of 0.1 percent, leaving it 11 percent below its 200-day average.
Should investors sell immediately? Or is it worth buying Medtronic?
Analysts tracked the transaction closely. Piper Sandler reiterated a “Hold” rating with an $85 price target, sticking with a neutral stance after surveying specialists. Those physicians anticipate market share gains for Medtronic’s InterStim and Altaviva systems, which could underpin annual revenue growth, though the analysts flagged persistent softness in parts of the neuromodulation business as a reason for caution. BTIG had already adjusted its view on Monday, trimming its target to $99 from $100 while keeping a “Buy” rating.
Clinical and Regulatory Momentum
Beyond the portfolio cleanup, Medtronic is pressing ahead on the operating side. Two-year data confirmed that the Altaviva implant maintains its effectiveness against urge incontinence, and the company launched ENDURANCE, a multi-year observational program across thirty sites designed to capture long-term outcomes and real-world adherence.
On the reimbursement front, the American Medical Association granted Category I CPT billing codes for the Altaviva and Symplicity Spyral systems on October 1. Those codes take effect in January 2028 and give clinicians long-range planning certainty. The company also secured FDA clearance for its Affera Prism-2 mapping software, which already carries the CE mark in Europe, while the PulseSelect ProxBox adapter with proximity indicator picked up its own CE certification. With MiniMed now behind it, Medtronic is channeling its focus toward these higher-margin growth areas.
Ad
Medtronic Stock: Buy or Sell?! New Medtronic Analysis from October 15 delivers the answer:
The latest Medtronic figures speak for themselves: Urgent action needed for Medtronic investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 15.
Medtronic: Buy or sell? Read more here...
